Von Hippel-Lindau disease tumor suppressor

BT-AP15470

Rabbit

IgG

100ul,50ul,20ul

Polyclonal

The antiserum was produced against synthesized peptide derived from human VHL around the phosphorylation site of Ser68. AA range:34-83

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

1 mg/ml

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

-20°C for 1 year

Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed.

Human: P40337; Mouse: P40338; Rat: Q64259;

24153

Human: 7428; Mouse: 22346; Rat: 24874

Von Hippel-Lindau disease tumor suppressor; VHL; Von Hippel-Lindau disease tumor suppressor; Protein G7; pVHL

Metabolism; Cancer; Cell biology; Epigenetics and nuclear signaling

VHL